Imagen de Portada

Discovery of novel 2,4-diarylaminopyrimidine hydrazone derivatives as potent anti-thyroid cancer agents capable of inhibiting FAK

Guardado en:
Publicado en:Journal of Enzyme Inhibition and Medicinal Chemistry vol. 39, no. 1 (Dec 2024)
Autor principal: Li, Hongting
Otros Autores: Mei-Qi Jia, Zhao-Long, Qin, Lu, Changliang, Chu, Weili, Zhang, Ze, Niu, Jinbo, Song, Jian, Sai-Yang, Zhang, Fu, Lijun
Publicado:
Taylor & Francis Ltd.
Materias:
Cytotoxicity
Cell migration
Thyroid cancer
Phosphorylation
Pharmacokinetics
Focal adhesion kinase
Cell proliferation
Thyroidectomy
Hydrogen bonds
Pharmaceutical sciences
Cancer therapies
Clinical trials
Chemistry
Design
Enzymes
Kinases
Acceso en línea:Citation/Abstract
Full Text - PDF
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Resumen:In this work, thirty 2,4-diarylaminopyrimidine-based hydrazones were designed, synthesised, and their anti-thyroid cancer activity were explored. The majority of compounds exhibit moderate to excellent cytotoxic activity against FAK overexpressing TPC-1 cells, with IC50 values ranging from 0.113 to 1.460 μM. Among them, compound 14f displayed exceptional anti-proliferative effect against TPC-1 cells (IC50 = 0.113 μM) and potent FAK inhibitory potency (IC50 = 35 nM). In silico studies indicated that compound 14f could well bind to FAK (Focal Adhesion Kinase) and have favourable pharmacokinetic profiles. In addition, compound 14f could inhibit the phosphorylation of FAK at Tyr397, Tyr576/577 and Tyr925, and did not affect the expression level of FAK in TPC-1 cells. Compound 14f was also effective in inhibiting the proliferation and migration of thyroid cancer cells TPC-1. Thus, these novel 4-arylaminopyrimidine hydrazone derivatives exhibited potent anti-thyroid cancer activities through the inhibition of FAK.
ISSN:1475-6366
1475-6374
8755-5093
DOI:10.1080/14756366.2024.2423875
Fuente:Health & Medical Collection